HISTORY


  •  

    2007

    Construction of new production campuses at Çerkezköy and Köseköy/İzmit gets underway.


  •  

    2007

    EastPharma acquires Saba Pharmaceuticals


  •  

    2007

    EastPharma conducts an IPO on the London Stock Exchange (GDRs).


  •  

    2007

    EastPharma’s head office relocates to new Premises.


  •  

    2008

    DEVA Holding’s 50 years of success were celebrated throughout Turkey with physicians and pharmacists.


  •  

    2008

    The new Çerkezköy Penicilin unit started production. The new injectables production unit in Köseköy was approved by the Ministry of Health.


  •  

    2008

    Incorporation date of DEVA has been celebrated together with the opening ceremony of the Çerkezköy Penicillin unit. The cephalosporin unit was successfully validated during the mid-September to mid-October period. The new, centralized warehouse in Çerkezköy was approved by the Turkish Ministry of Health.


  •  

    2008

    The test batch production and GMP inspection in the cephalosporin unit were performed. Registration of batch production for the new injectables production unit in Köseköy started. New management appointments.


  •  

    2008

    Construction of the new main production unit in Çerkezköy is almost completed and waiting to receive its GMP inspection. Restructuring of sales team was completed.


  •  

    2008

    EastPharma S.a.r.l. participated in the capital increase in DEVA Holding by making a further advance payment of TRY 36.45mn to DEVA Holding regarding the capital increase of DEVA Holding to TRY 144mn.


  •  

    2010

    DEVA Holding, the leading drug manufacturer in Turkey, delivers its aid package consisting of 1.581 parcels of medicine worth a total of 2.4 million Turkish Liras to the Turkish Red Crescent Society.


  •  

    2010

    DEVA acquired from Bristol-Myers Squibb Company the pharmaceutical products on the exclusive basis in Turkey.


  •  

    2010

    DEVA has completed the acquisition of a manufacturing and research facility from Zentiva. The facility is located adjacent to DEVA’s new factory at Cerkezkoy, and is dedicated to the manufacture of active pharmaceutical ingredients (API) and to research. The facility is 18.742 sq meters built on a site totalling 67.551 sq meters. The acquisition includes all machinery and equipment in the facility. DEVA has also been granted license rights over certain APIs for production, sale and export. In 2010, DEVA Holding joins with DEVA İlaç Sanayi ve Ticaret A.Ş.


  •  

    2010

    In 2010, DEVA Holding joins with DEVA İlaç Sanayi ve Ticaret A.Ş.

  •  

    2011

    DEVA Ilac Sanayi ve Ticaret A.S. (’DEVA Ilac’) is now under the consolidated roof of DEVA Holding A.S. The merger will serve as a strong platform to decrease operational costs and increase the efficiency and effectiveness of overall management and audit coordination.license rights over certain APIs for production, sale and export. In 2010, DEVA Holding joins with DEVA İlaç Sanayi ve Ticaret A.Ş.


  •  

    2011

    DEVA’s issued capital will increase from 180,070,656 Turkish Liras to 200,000,000 Turkish Liras. Following the issue DEVA will still remain below it’s registered capital ceiling of 500,000,000 Turkish Liras. EastPharma S.a.r.l. will take up its full entitlement in DEVA shares at a total cost of 16,384,368.68 Turkish Liras, so that percentage of DEVA shares held by EastPharma S.a.r.l will remain unchanged at 82.21%. DEVA's capital increased to 200.000.000 TRY At the end of 2011, 42 new product development projects have been completed.


  •  

    2011

    DEVA's capital increased to 200.000.000 TRY

  •  

    2011

    At the end of 2011, 42 new product development projects have been completed.

  •  

    2012

    In 2012, production facilities of DEVA Holding audited by German Ministry of Health last month received approval of compliance with European GMP (Good Manufacturing Practice)

  •  

    2012

    In 2012, first registration application to FDA has been realized.

  •  

    2013

    2013 Registered supplier of UN. DEVA was deemed worthy of the first prize in the “R&D Study of the Year” branch of the Golden Mortar competition.


  •  

    2014

    Inhaler manufacturing site opened. FDA ANDA submission 107 approval in 19 countries inc. Germany, Switzerland, Holland, Australia, New Zeland


  •  

    2015

    2013 Registered supplier of UN. DEVA was deemed worthy of the first prize in the “R&D Study of the Year” branch of the Golden Mortar competition.


  •  

    2015

    DEVA, was selected as the Best R&D Company by Eczacı Magazine.